For decades, cholesterol treatment meant one conversation: which statin, and what dose. Statins remain the foundation — decades of evidence, low cost, and outsized benefit. But the 2026 dyslipidemia guideline formally incorporates five lipid-lowering therapies approved by the FDA since the last guideline, and with lower LDL targets now in effect, combination therapy is becoming the norm for higher-risk patients rather than the exception.
The Expanded Toolkit
- Ezetimibe — not new, but newly central. An inexpensive daily tablet that blocks cholesterol absorption and typically adds 15–25% LDL lowering on top of a statin. Often the first add-on when a target is out of reach.
- PCSK9 monoclonal antibodies (evolocumab, alirocumab) — self-administered injections every 2–4 weeks that lower LDL by 50–60% beyond statins, with proven reductions in heart attack and stroke.
- Inclisiran — a small-interfering-RNA therapy that silences PCSK9 production at its source. After the initial doses, it is administered just twice a year in the office — an option that effectively eliminates the daily-adherence problem.
- Bempedoic acid — an oral agent that works upstream of statins in the same pathway but is not activated in muscle tissue, making it a well-studied option for statin-intolerant patients — with cardiovascular outcome data of its own.
- Icosapent ethyl — a purified omega-3 for patients with elevated triglycerides on statin therapy, with demonstrated cardiovascular event reduction in that group.
- Evinacumab — for the rare, severe inherited disorder homozygous familial hypercholesterolemia, a genuinely new mechanism for the patients who need it most.
"I Can't Take Statins" Is Now a Starting Point, Not a Dead End
The guideline takes statin intolerance seriously — and gives it a pathway. True muscle-related intolerance is less common than reported symptoms suggest, so the first step is a careful re-challenge strategy: different statin, lower dose, alternate-day dosing. But when intolerance is real, the toolkit above means an aggressive LDL goal is still fully achievable without a statin at all. Nobody should be living with an LDL of 160 because one medication didn't agree with them a decade ago.
How We Choose: The Right Tool for the Right Patient
Matching therapy to patient is genuine clinical work. How far are you from your target? What's your kidney and liver picture? How do you feel about injections versus pills? Is adherence realistic with a daily regimen, or is twice-a-year dosing the honest answer? Does cost or coverage steer the sequence? These decisions benefit from a cardiologist who knows your whole picture — and revisits it, because the first regimen is rarely the final one.
The Cardiolucent Approach
Dr. Kedan personally manages every medication decision through our guideline-directed medical therapy program, calibrated to the 2026 targets. And because polypharmacy is real, our medication coordination and reconciliation service makes sure the lipid regimen fits sensibly into everything else you take — streamlined, deconflicted, and reviewed with your other physicians. If your cholesterol plan hasn't been revisited since the new guideline, it's worth a fresh look: the targets moved, and the toolkit grew.
Source: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia — a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, published in Circulation and the Journal of the American College of Cardiology, March 2026.